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A commentary on
Skp2 is a promising therapeutic target in 
breast cancer
by Wang, Z., Fukushima, H., Inuzuka, H., 
Wan, L., Liu, P., Gao, D., Sarkar, F. H., and 
Wei, W. (2012). Front. Oncol. 1:57. doi: 
10.3389/fonc.2011.00057
The recent article by Wang et al. (2012a) 
was highly interesting. Interestingly, recent 
data suggests that Skp2 expression may play 
a significant role in the etio-pathogenesis of 
a number of systemic malignancies besides 
breast carcinomas.
For instance, the expression of Skp2 in 
prostate cancers is decreased by andro-
gens and is mediated via pathways that are 
dependent on p107 as well as pathways that 
are independent of p107 (Jiang et al., 2012). 
Similarly, accentuated Skp2 expression 
in prostate carcinomas may result in the 
loss of the tumor suppressor gene BRCA2 
(Arbini et al., 2011). Thus Skp2 may be a 
potential therapeutic target for the man-
agement of prostate malignancies (Wang 
et al., 2012b).
Similarly, the prognosis on ovarian 
cancers is influenced by Skp2. In fact, 
Skp2 expression by ovarian carcinomas 
is significantly associated with not only 
tumor stage but also lymph node metas-
tasis (Lu et al., 2012). Skp2 also is as a 
receptor for dihydro-testosterone. As a 
result dihydro-testosterone regulates p27 
degradation in ovarian carcinomas (Shi 
et al., 2011).
Similarly, resistance toward tumor necro-
sis factor related apoptosis inducing ligand 
(TRAIL) induced apoptosis in gastroin-
testinal malignancies especially pancreatic 
carcinomas is mediated by Skp2 (Schuler 
et al., 2011). This makes Skp2 a potential 
onco-target in the management of pancre-
atic malignancies. A similar association is 
seen in salivary carcinomas. Accentuated 
Skp2 expression is associated with decreased 
survival probability rates and a worse clinical 
outcome (Ben-Izhak et al., 2009).
Similarly, Skp2 has a role to play in 
the etio-pathogenesis of lung carcino-
mas. Non-small cell lung cancers typically 
demonstrated increased Skp2 expression. 
It promotes cellular invasion in pulmonary 
malignancies by up regulating matrix met-
alloproteinase-9 (MMP-9) as well as matrix 
metalloproteinase-2 (MMP-2; Hung et al., 
2010). Not surprisingly, agents such as 
tubocapsanolide A attenuate the expres-
sion of Skp2 and thereby have a negative 
effect on cellular proliferation in pulmo-
nary malignancies (Chang et al., 2007). 
Interestingly, WIF1 causes inhibition of 
proliferation in tumors such as bladder 
carcinomas by modulating Skp2 function 
besides regulating the expression of c-myc 
(Tang et al., 2009).
Clearly, Skp2 is involved in the patho-
genesis of a number of systemic malignan-
cies. It is a potential onco-target and further 
studies are needed to further identify com-
pounds that can target Skp2 expression.
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